UNSPSC 51292908: Mirtazapine

This classification denotes an antidepressant agent with the molecular formula C17H19N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A051Q2099Q, chemically known as 1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine but generally known as mirtazapine, which bears US NIH Compound Identifier 4205. European Medicines Agency schedules Mirtazapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08996MIG.

UNSPSC 51292908 Mirtazapine, a Commodity code, nominally identifies a specific antidepressant pharmaceutical product; however, recent state and local solicitations tagged under this code do not center on mirtazapine itself but instead reflect broader pharmaceutical procurement activity spanning naloxone, generic multi-source drugs, over-the-counter products, and direct-to-manufacturer prescription program infrastructure. State and local governments use this code tier to buy pharmaceutical supplies through competitive bidding processes, cooperative purchasing agreements, and exploratory market-intelligence initiatives. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The solicitations show a mix of direct pharmaceutical procurement, centralized cooperative contracting across multiple jurisdictions, and strategic procurement planning to reshape pharmacy benefit delivery models.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida posted IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (noting an apparent date discrepancy in the source). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state-level strategic procurement planning outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026. Vendors responding to MMCAP must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with authorized wholesalers, and accept a 3 percent administrative fee on all contract purchases. The code shows activity concentrated in direct procurement and cooperative purchasing vehicles rather than single-vendor sole-source arrangements.